About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Future Directions in the Targeting of HER2+ Breast Cancer: duration of trastuzumab therapy
By
Holy Cross 9th Annual Winter Oncology Symposium
FEATURING
Beverly Moy
April 23, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
18:15
Novartis Oncology
CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…
Feat.
G. Hortobagyi
Featured Video
13:03
Novartis Oncology
CDK4/6 Inhibitor Option for HR+/HER2- mBC: Are All CDK4/6 Inhibitors…
Feat.
D. Slamon
Related Content
AUTOPLAY
ON
49:07
SABCS 2022 Conference Coverage
SABCS 2022 Expert Panel Discussion: Practice-Changing Updates
Feat.
J. O'Shaughnessy,
S. Tolaney,
S. Hurvitz,
H. Rugo
57:44
Vogl, NY
Vogl,NY on How to Ask Good Questions at Medical Meetings
Feat.
S. Vogl
20:42
Total Health
2022 Updates in TNBC
Feat.
I. Schlam
05:45
SABCS 2022 Conference Coverage
SABCS 2022 Adjuvant Paclitaxel & Trastuzumab for Node- HER2+ BC:…
Feat.
S. Tolaney
03:24
ecancer
SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…
Feat.
V. Kaklamani
13:32
13th Annual Winter Breast Cancer Symposium
2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs
Feat.
W. Gradishar
20:16
University of Colorado Cancer Center
Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…
Feat.
V. Borges
07:34
PrecisCa
Summary of the Updated Results of SOFT/TEXT Trials and the Meta-Anal…
Feat.
M. Pegram
26:28
2023 West Oncology Conference
Antibody Drug Conjugates for Breast Cancer: The End of Chemotherapy?
Feat.
L. Schwartzberg
09:32
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "TROPiCS-02 Phase 3 Study Final OS Analysi…
Feat.
S. Tolaney
08:41
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "10-Year Update of the Short-HER Phase III…
Feat.
P. Conte
10:54
Yale Cancer Center
De-Escalation of Adjuvant Therapy in Early Stage HER2+ Breast Cancers
Feat.
L. Pusztai
10:22
ESMO 2022 Conference Coverage
ESMO 2022 Updates on mTNBC
Feat.
L. Carey
07:49
ESMO Breast Cancer 2023 Congress Coverage
ESMO Breast Cancer 2023 KEYNOTE-355 Trial: Outcomes in TNBC Patients…
Feat.
H. Rugo
12:23
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: Role of Endocrine Therapy Timing Intake in Pts …
Feat.
S. Giacchetti
26:03
Total Health
HR+ mBC: Optimizing Endocrine Therapy
Feat.
J. O'Shaughnessy
19:05
International Congress on Cancer Metastasis
Could We Cure Metastatic Breast Cancer?
Feat.
L. Pusztai
04:09
ecancer
Management of HER2+ mBC Treatment Algorithm
Feat.
S. Swain
14:11
ESMO Breast Cancer 2023 Congress Coverage
ESMO Breast Cancer 2023 Highlights: Key Studies Including IMPassion0…
Feat.
P. Tarantino
09:24
The University of Kansas Cancer Center
Treatment Sequence in mTNBC
Feat.
P. Sharma
